Treatment of hepatitis C in HCV mono-infected and in HIV-HCV co-infected patients: an open-labelled comparison study

Publikation

Treatment of hepatitis C in HCV mono-infected and in HIV-HCV co-infected patients: an open-labelled comparison study

Wissenschaftlicher Artikel/Review - 19.07.2010

Gonvers Jean-Jacques, Troilliet Nicolas, Negro Francesco, Monnat Martine, Malinverni Raffaelle, Dutoit Valérie, Dufour François, Chuard Christian, Chave Jean-Philippe, Cerny Andreas, Borovicka Jan, Bernasconi Enos, Genné Daniel, Mullhaupt Beat, Cavassini Matthias, Heim Markus H, Oneta Carl

Zitation

Gonvers J, Troilliet N, Negro F, Monnat M, Malinverni R, Dutoit V, Dufour F, Chuard C, Chave J, Cerny A, Borovicka J, Bernasconi E, Genné D, Mullhaupt B, Cavassini M, Heim M, Oneta C. Treatment of hepatitis C in HCV mono-infected and in HIV-HCV co-infected patients: an open-labelled comparison study. Swiss Med Wkly 2010; 140:w13055.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Swiss Med Wkly 2010; 140

Veröffentlichungsdatum

19.07.2010

eISSN (Online)

1424-3997

Seiten

w13055

Kurzbeschreibung/Zielsetzung

Treatment of chronic HCV infection has become a priority in HIV+ patients, given the faster progression to end-stage liver disease. The primary endpoint of this study was to evaluate and compare antiviral efficacy of Peginterferon alpha 2a plus ribavirin in HIV-HCV co-infected and HCV mono-infected patients, and to examine whether 6 months of therapy would have the same efficacy in HIV patients with favourable genotypes 2 and 3 as in mono-infected patients, to minimise HCV-therapy-related toxicities. Secondary endpoints were to evaluate predictors of sustained virological response (SVR) and frequency of side-effects.